The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines

T Hultsch, R Martin, R J Hohman, T Hultsch, R Martin, R J Hohman

Abstract

The immunosuppressive drugs FK506 and cyclosporin A have an identical spectrum of activities with respect to IgE receptor (Fc epsilon RI)-mediated exocytosis from mast cells and T cell receptor-mediated transcription of IL-2. These findings suggest a common step in receptor-mediated signal transduction leading to exocytosis and transcription and imply that immunosuppressive drugs target specific signal transduction pathways, rather than specific cell types. This hypothesis is supported by studies on the effect of rapamycin on IL-3 dependent proliferation of the rodent mast cell line PT18. Rapamycin inhibits proliferation of PT18 cells, achieving a plateau of 80% inhibition at 1 nM. This inhibition is prevented in a competitive manner by FK506, a structural analogue of rapamycin. Proliferation of rat basophilic leukemia cells and WEHI-3 cells was also inhibited, at doses comparable to those shown previously to inhibit IL-2-dependent proliferation of cytotoxic T lymphocyte line (CTLL) cells. In contrast, proliferation of A-431 cells, a epidermoid cell line, was not affected by rapamycin. DNA histograms indicate that complexes formed between the rapamycin-FK506-binding protein (FKBP) and rapamycin arrest-proliferating PT18 cells in the G0/G1-phase. It is concluded that FKBP-rapamycin complexes may inhibit proliferative signals emanating from IL-3 receptors, resulting in growth arrest of cytokine-dependent, hematopoietic cells.

References

    1. Nature. 1992 Jun 25;357(6380):692-4
    1. Science. 1984 Dec 21;226(4681):1439-41
    1. Science. 1990 Oct 26;250(4980):556-9
    1. Science. 1991 Jan 18;251(4991):283-7
    1. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6677-81
    1. Cell. 1991 Aug 23;66(4):807-15
    1. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8905-9
    1. Nature. 1990 Apr 5;344(6266):503-8
    1. New Biol. 1990 Aug;2(8):663-72
    1. J Exp Med. 1989 Jul 1;170(1):245-57
    1. Nature. 1989 Oct 26;341(6244):758-60
    1. J Immunol. 1989 Jun 1;142(11):3796-802
    1. Annu Rev Immunol. 1986;4:419-70
    1. J Immunol. 1984 Mar;132(3):1479-86
    1. Proc Natl Acad Sci U S A. 1984 Aug;81(16):5214-8
    1. Nature. 1992 Jun 25;357(6380):695-7
    1. Cell. 1991 Aug 23;66(4):731-42
    1. Nature. 1991 Sep 12;353(6340):174-7
    1. Eur J Immunol. 1990 Oct;20(10):2277-83
    1. J Immunol. 1991 Apr 1;146(7):2374-81
    1. Proc Natl Acad Sci U S A. 1991 Jul 15;88(14):6229-33
    1. Science. 1991 Aug 23;253(5022):905-9
    1. Biochem Pharmacol. 1991 Aug 22;42(6):1221-8
    1. Mol Cell Biol. 1991 Mar;11(3):1185-94
    1. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9231-5
    1. Nature. 1990 Sep 13;347(6289):189-91
    1. Science. 1990 Jan 19;247(4940):324-7
    1. Nature. 1989 May 4;339(6219):64-7
    1. Nature. 1989 Oct 26;341(6244):755-7
    1. Nature. 1989 May 11;339(6220):150-2
    1. Science. 1989 Nov 3;246(4930):614-21
    1. Prog Allergy. 1988;42:185-245
    1. Blood. 1988 Mar;71(3):684-9
    1. J Cell Biol. 1984 Jun;98(6):2250-4
    1. Science. 1984 Nov 2;226(4674):544-7
    1. Immunol Today. 1992 Feb;13(2):63-8

Source: PubMed

3
Subskrybuj